OptimizeRx OPRX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | $11.47M-16.4% | $13.72M-12.9% | $15.75M+187% | ||
| $4.33M-0.1% | $4.33M+80.2% | $2.4M+18.8% | $2.02M— | ||
| —— | —— | —— | —— | ||
| $5.13M+126% | -$20.11M-14.5% | -$17.57M-53.6% | -$11.44M-3,125% | ||
| $368K-95.1% | $7.49M— | —— | —— | ||
| $1.11M+32.9% | $835K+296% | $211K— | —— | ||
| —— | 3%0.0% | 3%— | —— | ||
| $1.84M+1,043% | $161K+235% | $48K— | —— | ||
| —— | -$72K+94.5% | -$1.32M-240% | $943.17K+8,343% | ||
| —— | $2.17M— | —— | —— | ||
| —— | $1.05M— | —— | —— | ||
| —— | $301K— | —— | —— | ||
| —— | —— | —— | $226— | ||
| —— | -$811K— | —— | —— | ||
| $4.18M-32.5% | $6.2M+411% | $1.21M— | —— | ||
| -$8.8M-79.1% | -$4.91M-117% | $28.22M+249% | -$18.95M-126% | ||
| $68K+115% | -$450K+98.2% | -$25.34M+56.4% | -$58.18M-11,870% | ||
| $18.72M+283% | $4.89M— | —— | $10.65M— | ||
| —— | $911K— | —— | —— | ||
| $58K-48.2% | $112K+28.7% | $87K+7.4% | $81.01K-19.3% | ||
| —— | $338K-56.9% | $784K+379% | $163.56K-55.1% | ||
| $0-100% | $208K-68.8% | $666K+83.2% | $363.51K+354% | ||
| $8M+100% | $4M+134% | $1.71M— | —— | ||
| $6.96M-39.3% | $11.47M-16.4% | $13.72M-12.9% | $15.75M+187% | ||
| $16.03M— | —— | -$23.97M-133% | -$10.27M-543% | ||
| $11.71M— | —— | -$26.37M-115% | -$12.29M-3,504% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is OptimizeRx's revenue?
- OptimizeRx (OPRX) generated $107.3M in revenue over the trailing twelve months, up 39.8% year over year.
- Is OptimizeRx profitable?
- OptimizeRx reported $6.8M in net income over the trailing twelve months, a 6.4% net margin.
- What are OptimizeRx's profit margins?
- Gross margin is 70.0% and operating margin is 13.2%, with a 6.4% net margin.
- What is OptimizeRx's earnings per share?
- OptimizeRx's diluted EPS over the trailing twelve months is $0.35.
- Where does OptimizeRx's income statement data come from?
- Every line is extracted from OptimizeRx's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
